Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25886101 | 0.88 | LTA4H (0.37) | HRH3DRD2HTR4 | |
| SCHEMBL25467315 | 0.87 | HRH3 (0.39) | HRH3DRD2DRD3HTR4OPRD1 | |
| SCHEMBL25831683 | 0.86 | HRH3 (0.40) | HRH3DRD2DRD3HTR4OPRD1 | |
| SCHEMBL23945877 | 0.86 | HRH3 (0.40) | HRH3DRD2DRD3HTR4OPRD1 | |
| SCHEMBL23945314 | 0.85 | MEN1 (0.42) | HRH3DRD2HTR4KMT2AALDH1A1 | |
| SCHEMBL25698973 | 0.84 | MEN1 (0.40) | DRD2HTR4KMT2AALDH1A1CHRM1 | |
| SCHEMBL23806856 | 0.82 | CARM1 (0.33) | HRH3HTR4KMT2AKDM4E | |
| SCHEMBL25477755 | 0.81 | PRMT6 (0.37) | HRH3KMT2AKDM4E | |
| SCHEMBL25698992 | 0.79 | USP2 (0.38) | HRH3DRD2DRD3HTR4CHRM1 | |
| SCHEMBL24508674 | 0.79 | ACHE (0.45) | DRD2DRD3KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | HRH3 1734/4885DRD2 3892/4885DRD3 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.